I agree.
This was published last night in Nature Cancer, "Targeting the innate immune system in pediatric and adult AML."
https://www.nature.com/articles/s41375-024-02217-7
I've rewatched this presentation several times but its making a lot of sense.
https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02710995-69UCCL0B3668NS2PSD1Q0C53O2/pdf?access_token=0007rInP8VKAEnFJfs0cXGTQyMga
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-24
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
0.001(3.13%) |
Mkt cap ! $14.63M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.7¢ | 1.6¢ | $1.242K | 76.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 2409370 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 718819 | 5 |
View Market Depth
| Last trade - 12.25pm 27/08/2024 (20 minute delay) ? |
| CHM (ASX) Chart |